You are seeing these quotes based on previous browsing related to sectors such as
Latest | Forecast | |
---|---|---|
Div Yield | 0.0% | n/a |
Div Cover | n/a | n/a |
Op Mrgn | 0.0% | n/a |
ROCE | 0.0% |
Latest | Forecast | |
---|---|---|
P/E | -3.6 | n/a |
PEG | 0.0 | n/a |
Price / Revenue | 0.0 | n/a |
Price / Book value | 2.3 |
Latest | Forecast | |
---|---|---|
Revenue | n/a | n/a |
PBT | 0.0% | n/a |
EPS | 0.0% | n/a |
DPS | n/a | n/a |
Year Ending | Revenue (£m) |
Pre-tax (£m) |
EPS | P/E | PEG | EPS Growth | Div | Yield |
---|---|---|---|---|---|---|---|---|
2020-12-31 | n/a | -0.51 | -1.89p | 0.0 | 0.0 | n/a | n/a | 0.0% |
2021-12-31 | n/a | -2.53 | -6.02p | -4.9 | 0.0 | n/a | n/a | 0.0% |
2022-12-31 | n/a | -2.97 | -3.78p | -4.5 | 0.0 | n/a | n/a | 0.0% |
Michael Kauffman promoted to BiVictriX board chair Sharecast News | 06 Jan |
---|---|
BiVictriX identifies development lead for potential cancer drug Sharecast News | 07 Dec |
BiVictriX upbeat on recent pipeline progress Sharecast News | 11 Jul |
BiVictriX nominates clinical candidate for BVX001 | 06-Jun-23 14:28 |
---|---|
Result of Annual General Meeting | 04-May-23 23:58 |
Publication of Annual Report and Notice of AGM | 31-Mar-23 14:58 |
BiVictriX Full Year Results | 30-Mar-23 15:08 |